De Novo device
Notal Vision Home Optical Coherence Tomography (OCT) System
Notal Vision, Inc. · Home Monitoring Ophthalmic Optical Coherence Tomography (Oct) Imaging Device (SAX, Class II) · First FDA decision May 15, 2024, newest May 15, 2024Macular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
4
Naming "Notal Vision"
MAUDE reports
0
Brand "Notal Vision", since 2015
PubMed studies
10
Mentioning "Notal Vision"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Notal Vision Home Optical Coherence Tomography (OCT) System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Notal Vision Home Optical Coherence Tomography (OCT) SystemNew device typeBreakthroughDe Novo
DEN230043 · Decided May 15, 2024 · 343 days after receipt
Device type: Home Monitoring Ophthalmic Optical Coherence Tomography (Oct) Imaging Device (SAX) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected DementiaNational analysisReview closedCAG-00088RUpdated Sep 21, 2026
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)Local determinationIn effectL34061CGS Administrators, LLCUpdated Jul 27, 2026
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)Local determinationIn effectL34380Wellpoint FederalUpdated Jul 14, 2026
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)Local determinationIn effectL34760WPS Insurance CorporationUpdated Jun 17, 2025
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)Local determinationIn effectL33751First Coast Service Options, Inc.Updated Jan 28, 2022
- Scanning Computerized Ophthalmic Diagnostic ImagingLocal determinationIn effectL35038Novitas Solutions, Inc.Updated Dec 10, 2021
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)Local determinationIn effectL34431Palmetto GBAUpdated Aug 2, 2021
Clinical trials
Device studies on ClinicalTrials.gov that name "Notal Vision", any status and sponsor, newest update first.
Rabin Medical CenterAcademic, hospital or other
NCT07744984 · 12 participants · Start Jul 3, 2024 · Primary completion Apr 1, 2026
Device: Home Optical Coherence Tomography (Home OCT) · For: Age-Related Macular Degeneration (AMD); Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Sites: Petah Tikva, Israel
- Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCTStatus unknown
Notal Vision Inc.Not on our public-company list
NCT05745116 · 150 participants (planned) · Start Nov 7, 2022 · Primary completion Jul 31, 2023
Device: Notal Vision Home OCT · For: Diabetic Macular Edema
Sites: Baltimore, Maryland; Fairfax, Virginia; Norfolk, Virginia
- ForeseeHome NRich RegistryActive, not recruiting
Notal Vision Inc.Not on our public-company list
NCT05690880 · 20,000 participants (planned) · Start Dec 15, 2022 · Primary completion Dec 15, 2027
Device: Foresee Home · For: Age-Related Macular Degeneration
Sites: Toms River, New Jersey
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Notal Vision", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SAX
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Notal Vision"[tiab]. The summary above synthesizes these.
- Prospective, Longitudinal Pilot Study: Daily Self-Imaging with Patient-Operated Home OCT in Neovascular Age-Related Macular Degeneration.
Keenan TDL, Goldstein M, Goldenberg D, et al. · Ophthalmol Sci · 2021
- Prospective, Longitudinal Study: Daily Self-Imaging with Home OCT for Neovascular Age-Related Macular Degeneration.
Liu Y, Holekamp NM, Heier JS · Ophthalmol Retina · 2022Observational Study, Research Support, Non-U.S. Gov't
- Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study.
Blinder KJ, Calhoun C, Maguire MG, et al. · Ophthalmol Retina · 2024Observational Study, Research Support, Non-U.S. Gov't
- Evaluation of a self-imaging SD-OCT system designed for remote home monitoring.
Kim JE, Tomkins-Netzer O, Elman MJ, et al. · BMC Ophthalmol · 2022
- Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration.
Ho AC, Heier JS, Holekamp NM, et al. · J Clin Med · 2021
- Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4.
Domalpally A, Clemons TE, Bressler SB, et al. · Ophthalmol Retina · 2019Multicenter Study, Research Support, N.I.H., Intramural
- Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization.
Yu HJ, Kiernan DF, Eichenbaum D, et al. · Ophthalmol Retina · 2021Multicenter Study
- Evaluation of a Self-Imaging SD-OCT System for Remote Monitoring of Patients with Neovascular Age Related Macular Degeneration.
Nahen K, Benyamini G, Loewenstein A · Klin Monbl Augenheilkd · 2020
- Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study.
Chew EY, Clemons TE, Bressler SB, et al. · Ophthalmology · 2014Clinical Trial, Phase III, Comparative Study
- Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
Yu JS, Carlton R, Agashivala N, et al. · J Manag Care Spec Pharm · 2021Observational Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.